Mostrando 10 resultados de: 48
Filtros aplicados
Publisher
Pharmacogenomics(9)
Pharmacogenomics Journal(9)
Clinical Pharmacology and Therapeutics(3)
European Journal of Clinical Pharmacology(3)
European Journal of Drug Metabolism and Pharmacokinetics(2)
Área temáticas
Farmacología y terapéutica(34)
Enfermedades(11)
Fisiología humana(9)
Medicina y salud(6)
Anatomía humana, citología, histología(4)
High frequency and founder effect of the CYP3A4∗20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme
ArticleAbstract: Cytochrome P450 3A4 (CYP3A4) is a key drug-metabolizing enzyme. Loss-of-function variants have beenPalabras claves:Autores:Adrián LLerena, Apellániz-Ruiz M., Carracedo Á., Cascón A., Comino-Méndez I., Currás-Freixes M., De Cubas A.A., Grazina M., Ingelman-Sundberg M., Inglada-Pérez L., Mancikova V., Moya G.E., Naranjo M.E.G., Opocher G., Rasool M., Rebai A., Robledo M., Rodríguez-Antona C., Sánchez L., Taboada-Echalar P., Triki S.Fuentes:scopusHigh prevalence of CYP2D6 ultrarapid metabolizers in a mestizo Colombian population in relation to Hispanic mestizo populations
ArticleAbstract: Background: Interethnic differences in CYP2D6 allele frequency have been demonstrated across Latin-APalabras claves:COLOMBIA, CYP2D6, Hispanics, Mestizos, Ultrarapid metabolizersAutores:Adrián LLerena, Borbón-Orejuela A., de Andrés F., Dorado P., P Sarmiento A.Fuentes:scopusEvaluating a newly developed pharmacogenetic array: Screening in a Spanish population
ArticleAbstract: Aims: How genes affect the response in a patient to a given medication is still poorly understood; tPalabras claves:accuracy, CYP2D6, PHARMAChip array ®, pharmacogenetics, sensitivity, SLC6A4, Specificity, successful genotyping rateAutores:Abad-Santos F., Adrián LLerena, Almoguera B., Ayuso C., Dal-Ré R., Dorado P., Fernandez-Piqueras J., Gomez-Dominguez B., Lopez-Rodriguez R., Riveiro-Alvarez R., Vaquero-Lorenzo C.Fuentes:scopusGenetic factors in the metabolism of haloperidol.
ArticleAbstract:Palabras claves:Autores:Adrián LLerena, Bertilsson L., Dahl M.L., Ekqvist B.Fuentes:scopusGenetic structure of pharmacogenetic biomarkers in Brazil inferred from a systematic review and population-based cohorts: a RIBEF/EPIGEN-Brazil initiative
ArticleAbstract: We present allele frequencies involving 39 pharmacogenetic biomarkers studied in Brazil, and their dPalabras claves:Autores:Adrián LLerena, Andrade P.X.C., Aquino M.M., Céspedes-Garro C., Horta B.L., Kehdy F.S.G., Lima-Costa M.F., Mauricio L. Barreto, Pereira A.C., Rodrigues-Soares F., Sampaio-Coelho J., Tarazona-Santos E.M., Zolini C.Fuentes:scopusGenetic variability of CYP2C9∗2 and CYP2C9∗3 in seven indigenous groups from Mexico
ArticleAbstract: Aim: CYP2C9 is one of the major drug metabolizing enzymes, however, little is known about polymorphiPalabras claves:allele frequency, CYP2C9, hypoglycemic therapy, Mexican indigenous, pharmacogenetics, polymorphismAutores:Adrián LLerena, García-Rodríguez M., Granados-Silvestre M., Menjívar M., Ortiz-López M.G., Peña-Espinoza B., Rivera-Santiago C., Sánchez-Pozos K.Fuentes:scopusGenomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans
ArticleAbstract: We present the distribution of CYP2D6, CYP2C9, and CYP2C19 variants and predicted phenotypes in 33 nPalabras claves:Autores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Michelin L.A., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopusEthnic background and CYP2D6 genetic polymorphisms in Costa Ricans
ArticleAbstract: CYP2D6 differences have already been demonstrated within Latin American populations by the CEIBA.FPPalabras claves:Afro-Caribbean, Amerindian, COSTA RICA, CYP2D6, MESTIZO, Poor metabolizers, populations, Ultrarapid metabolizersAutores:Adrián LLerena, Barrantes R., Calzadilla L.R., Céspedes-Garro C., Enrique Terán, Estévez-Carrizo F.E., Grazina M., Jiménez-Arce G., López-López M., María-Eugenia G.N., Moya G.E., Ortiz-López R., Ramírez-Roa R., Rodeiro I., Sarmiento A.P., Sosa-Macías M.G., Tarazona-Santos E.M.Fuentes:scopusEating disorder symptoms and CYP2D6 variation in cuban healthy females: A report from the Ibero-American network of pharmacogenetics
ArticleAbstract: CYP2D6 is involved in the metabolism of antidepressants drugs and of the endogenous neurotransmitterPalabras claves:Cuban population, CYP2D6, Eating disorder symptoms, Global pharmacogenetics, Healthy females, Public health pharmacogenetics, Ultrarapid metabolizersAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Naranjo M.E.G., Penãs-Lledó E.M., Pérez B.Fuentes:scopusEffect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions
ArticleAbstract: Objectives: CYP2D6 drug-metabolising enzyme has been shown to be involved in fluoxetine metabolism iPalabras claves:CYP2C9, CYP2D6, Selective serotonin reuptake inhibitorsAutores:Adrián LLerena, Berecz R., Dorado P., González A.P., Penãs-Lledó E.M.Fuentes:scopus